AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
about
Prostate cancer relevant antigens and enzymes for targeted drug deliveryProtein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugateA phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptorChaperoning G protein-coupled receptors: from cell biology to therapeuticsEnhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine.Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2.Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cellsInhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonistsNovel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.Agonists of luteinizing hormone-releasing hormone in prostate cancer.Emerging drugs for urothelial carcinoma.Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectivesNatural product and natural product derived drugs in clinical trials.LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer.Pathway-based Bayesian inference of drug-disease interactions.Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines.Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the motility of human decidual endometrial stromal cells: possible effect on embryo implantation and pregnancy.Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention.On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.Trial Watch: Chemotherapy with immunogenic cell death inducers.GnRH Action
P2860
Q27013843-1BCACC25-FE1C-4FC5-8B55-C1A8AA32C972Q28537657-227E1E9F-D7F5-4F24-A956-4EE943FBB624Q33629937-DB7DBAAC-125E-4B92-A6EF-F0BB74761037Q33927508-8619784A-7DED-40DF-B505-B009E77578C4Q34402129-608D4843-64E3-4CE6-BF11-C3516BC112A8Q34779402-003DB247-1AED-4B13-9946-A88D96ADF998Q34894406-646EB48F-5572-4E5C-BF9F-2CF5AF5A02E5Q36236479-17CB79C8-F51F-4616-B8C6-A11DC562FD26Q36948906-F8E7E791-32FD-4D24-847D-FD07E6C60D32Q37029375-12B9FD4E-897D-45DB-90A9-BC89A0F5BF12Q37093547-DB8CF4E9-AF60-4C04-92EC-061233A4913FQ37495105-24F5FB1B-BFB8-4698-B1A9-733CD9234C69Q37724516-16908200-1DF2-4E95-8F0A-38350306975AQ38132229-4BFAB418-EE86-4A72-86A1-62E5A5E94095Q38160271-624B1BF6-A2CC-41DA-927C-9E5F09836743Q38216009-2D3D0468-3108-4D00-8BDE-684BE0099535Q38247457-C1C370EA-7060-4885-B8EB-CB7DF29547AAQ38999341-004A8377-8CBD-4603-83C7-9AAF90F0358DQ43435715-D6766F00-EAA2-4B3B-B123-BEA790E7083FQ47848539-58179E3E-BAE5-426E-86FA-12999CF6E022Q50350314-2934F6E6-DDC3-469B-BC3D-787EDF190DB2Q50865530-CEFD627B-EC68-4840-BDBD-68128D077CF4Q54285171-605314EA-8A60-429C-A40F-556CAC8168A0Q55018323-EFACF268-DD30-4B49-B438-460A3A9744E4Q55054276-6EA2F541-6A2A-4560-95C7-48496AABA04AQ55082165-19432C91-F2BD-4E65-A38A-3FA76A99D787Q55260834-A60E7577-BDE0-4B81-8568-A3B6943C823AQ57918892-C4DB7E19-397B-4B69-BDD2-88C2C768791E
P2860
AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@ast
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@en
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@nl
type
label
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@ast
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@en
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@nl
prefLabel
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@ast
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@en
AEZS-108 : a targeted cytotoxi ...... s positive for LHRH receptors.
@nl
P2860
P1476
AEZS-108 : a targeted cytotoxi ...... rs positive for LHRH receptors
@en
P2093
Guenter Emons
Jacek Pinski
P2860
P304
P356
10.1517/13543784.2012.685128
P407
P577
2012-06-01T00:00:00Z